RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Kudos To Independent For Debunking Nibiru "Blood Moon" Hoax
- It's Not The Nicotine: US Teens More Likely To Vape For Flavorings
- Your Microbiome Did Not Cause Your Weight Problem
- A Great Blitz Game
- Control Cancer By Making The Tumor Cell Environment Hostile
- On Sexuality, You Weren't Born That Way, Says Paper
- Beekeeping Fad And The Stress Of Traveling Is Harmful To Bees
- "Try chess24.com. It's free and a great site. And you can challenge me! ;-)..."
- "Yes I agree, it's especially sad when very young children get worried about this stuff, when there's..."
- "LocalFluff - just to say I didn't delete your comment on Stuart's post, or hide it - it was automatically..."
- "Yes I agree. I think there is a lot of hope as well, there are many who are working to save the..."
- "Oh that was just a joke. We have a way of telling jokes in the UK that we use sometimes - a very..."
- Another Kardashian Craze Debunked
- Fad Friday: Ditch The Body Wrap!
- Commonly Cited Stat of 10 Bacteria for Every 1 Human Cell Is Wrong
- Why The EpiPen And Other Generic Drugs Are So Expensive
- Latest IARC Report Connects Fatness with More Cancers
- Fact Checking Mylan Claims They Raised The EpiPen Price Because of Improvements
- UNIST to engineer next-generation smart separator membranes
- Important advance made with new approach to 'control' cancer, not eliminate it
- More to rainbows than meets the eye
- US teens more likely to vape for flavorings than nicotine in e-cigarettes
- Israeli lifestyle and environment may pose exceptional risks for Hodgkin's lymphoma